8-K: Profusa Secures $1.1M Financing and Issues Warrants

Profusa, Inc. issued a $1.11 million senior secured convertible note and 3.33 million warrants to Ascent Partners Fund LLC.

Summary

• Profusa, Inc. completed an additional closing under a February 2025 Securities Purchase Agreement.
• The company issued a Senior Secured Convertible Promissory Note with a principal amount of $1,111,111.11.
• The note matures on April 20, 2027, and carries a 12% annual interest rate payable in cash.
• The note is convertible into common stock at $0.50 per share.
• The company issued a warrant to purchase 3,333,333 shares of common stock at an exercise price of $0.50 per share.
• The warrant is exercisable for five years and includes anti-dilution protections.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative development; while it provides necessary liquidity, the high cost of capital, potential for significant dilution, and the need for a default waiver indicate ongoing financial pressure.

Positives

• Secured $1 million in gross proceeds to support company operations.
• The transaction includes a 120-day lock-up agreement on the warrant shares, limiting immediate selling pressure.
• The company successfully negotiated a waiver for a previous default related to the timing of warrant delivery.

Negatives

• The note was issued with an original issue discount (OID), meaning the company received $1,000,000 for a $1,111,111.11 obligation.
• The interest rate increases to 24% per annum upon an event of default.
• The issuance of 3.33 million warrants and the potential conversion of the note create significant potential dilution for existing shareholders.
• The company is required to pay a 5% cash payment fee on principal repayments made in cash under certain conditions.

Risks

• The company is subject to strict negative covenants, including restrictions on incurring additional debt, selling assets, or making restricted payments.
• Failure to meet financial obligations or covenants could trigger an event of default, leading to immediate acceleration of debt.
• The company's assets are pledged as collateral, increasing the risk to the business in the event of insolvency.
• The note and warrant contain beneficial ownership limitations (4.99% to 9.99%) that could complicate future capital structure management.

Future Outlook

The company intends to use the proceeds for general corporate purposes as defined in the original Purchase Agreement, while managing its debt obligations and potential equity conversions.

Management Comments

• Management has acknowledged the terms of the financing and the associated obligations under the Transaction Documents.

Industry Context

StockSavvy.ai notes that this type of high-interest, convertible debt with warrants is common for small-cap or pre-revenue biotech/medtech companies facing liquidity constraints, often signaling a need for bridge financing before a larger capital raise or milestone achievement.

Comparison to Industry Standards

• The 12% interest rate is consistent with high-risk, distressed, or bridge financing for small-cap companies.
• The use of OID and warrants is a standard mechanism for investors to achieve higher effective yields in speculative equity situations.
• The 9.99% beneficial ownership cap is a standard protective measure in private placement transactions.

Corporate Governance

Stakeholder Impact

• Shareholders face potential dilution from the conversion of the note and exercise of warrants.
• Creditors may be impacted by the senior secured nature of this debt, which ranks ahead of other obligations.

Next Steps

• Monitor for potential conversion notices from the holder.
• Track the expiration of the lock-up period on August 22, 2026.
• Observe compliance with monthly interest payments.

Key Dates

Recommendation

The company is relying on expensive, dilutive bridge financing to maintain operations. Investors should hold until there is evidence of a sustainable path to profitability or a non-dilutive funding source.

Keywords

Profusa, Convertible Note, Warrants, Financing, Securities Purchase Agreement, Dilution, Debt Financing